Patent Application for Tenosynovial Giant Cell Tumor Treatment
Summary
The USPTO has published a patent application (US20260085124A1) detailing compositions and methods for treating tenosynovial giant cell tumor using intra-articular delivery of anti-CSF1R antibodies. The application, filed by Kirk William Johnson, focuses on sustained drug exposure within joints.
What changed
This document is a patent application (US20260085124A1) filed with the USPTO, detailing novel methods for treating tenosynovial giant cell tumor. The application describes compositions and techniques for intra-articular delivery of anti-CSF1R antibodies, aiming for sustained therapeutic activity within joints beyond conventional short dwell times.
As this is a patent application, it does not impose immediate regulatory obligations or deadlines on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for specific joint diseases. Companies involved in drug development, particularly in oncology and rheumatology, may find this application relevant for competitive intelligence and potential licensing opportunities.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR
Application US20260085124A1 Kind: A1 Mar 26, 2026
Inventors
Kirk William Johnson
Abstract
The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a joint that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.
CPC Classifications
C07K 16/2866 A61P 35/00 A61K 2039/505 A61K 2039/54 A61K 2039/545
Filing Date
2023-09-11
Application No.
19111100
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.